2) Our returning guest author is Melvin Chan @MChanMD from @CUPedsNeph.
— @CKD_ce (@ckd_ce) April 15, 2024
Our topic for 🆓CE/#CME : Early Rituximab as an Add-On Therapy in Children with the Initial Episode of Nephrotic Syndrome#MedTwitter #nephtwitter @ISNkidneycare pic.twitter.com/20IfLFIzck
4) Let’s begin with a quiz: How many pediatric patients with steroid-sensitive #nephrotic syndrome relapse within the first year after initial steroid therapy?
— @CKD_ce (@ckd_ce) April 15, 2024
6) One question is whether #RTX infusion, after obtaining remission with steroids, can decrease remission during the first year
— @CKD_ce (@ckd_ce) April 15, 2024
We will review the recent article in @KIReports: Early RTX as an Add-On Therapy in Children With the Initial Episode of NS
🔓 https://t.co/kjNVh4LnhS
8) We discuss here a
— @CKD_ce (@ckd_ce) April 15, 2024
🔬Prospective, multicenter, open-label, single-arm clinical trial conducted at 8 🇨🇳🏥
🚩Control Group: Historical pts who rec'd 8wks or 12-14wks steroid therapy depending on remission time
🚩Treatment Group: See inclusion/exclusion; followed this protocol: pic.twitter.com/InqgOZhSXB
10) Primary Outcome: 1 year relapse-free rates
— @CKD_ce (@ckd_ce) April 15, 2024
Secondary Outcomes:
🔭Number of days from #RTX infusion to first relapse
🔭Six month relapse-free rates
🔭 🕐 to detection of #CD19 reconstitution
Exploratory Outcomes
🔎2 year relapse-free survival rate
🔎Incidence of #FRNS/#SDNS
12) Primary Outcome
— @CKD_ce (@ckd_ce) April 15, 2024
🔎74% of patients remained in remission
🚫differences in response based on sex, age at onset (>= 4 years or < 4 years), or days to remission (>= 10 days or 10 < days). pic.twitter.com/NZzaZIF5p9
14) Exploratory Outcomes
— @CKD_ce (@ckd_ce) April 15, 2024
🔎Lower incidence of frequently relapsing or steroid dependent #nephrotic syndrome at 12-month follow-up compared to controls (11.6% vs 42.4%, p=0.002)
🔎🔎Improved 2 year relapse-free survival pic.twitter.com/RrvucFuxab
16) Learning Points for Using #Rituximab at time of NS Onset
— @CKD_ce (@ckd_ce) April 15, 2024
💡Improved rates of remission at 1 year follow-up
💡Decreased rates of FRNS/SDNS
💡Well tolerated
18) Future Directions
— @CKD_ce (@ckd_ce) April 15, 2024
🔮A trial enrolling patients with higher risk of FRNS/SDNS
🔮A randomized control trial involving pediatric patients. (There is one underway but only includes adults:https://t.co/wseBQGx5zp)
19b) The answer is 2 times
— @CKD_ce (@ckd_ce) April 15, 2024
What were the other conclusions from this study?
a. 🔽 2 year relapses
b. 🔽 rates of FRNS/SDNS
c. RTX was safe
d. All of the above
20) The answer is D. You just earned 0.5hr CE/CME! Claim your certificate now at https://t.co/KZlki8Xmfe and share this #tweetorial with your followers and friends! Thanks to @MChanMD for authoring & @sophia_kidney for managing!#FOAMed #nephtwitter @ISNkidneycare @KIReports
— @CKD_ce (@ckd_ce) April 15, 2024